Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Restoration of hypoxia-induced apoptosis in tumors harboring
p53
mutations has been proposed as a potential therapeutic strategy; however, the transcriptional targets that mediate hypoxia-induced
p53
-dependent apoptosis remain elusive. Here, we demonstrated that hypoxia-induced
p53
-dependent apoptosis is reliant on the DNA-binding and transactivation domains of
p53
but not on the acetylation sites K120 and K164, which, in contrast, are essential for DNA damage-induced,
p53
-dependent apoptosis. Evaluation of hypoxia-induced transcripts in multiple cell lines identified a group of genes that are hypoxia-inducible proapoptotic targets of
p53
, including inositol polyphosphate-5-phosphatase (INPP5D), pleckstrin domain-containing A3 (PHLDA3), sulfatase 2 (SULF2), B cell translocation gene 2 (BTG2), cytoplasmic FMR1-interacting protein 2 (CYFIP2), and
KN motif and ankyrin repeat domains 3
(
KANK3
). These targets were also regulated by
p53
in human cancers, including breast, brain, colorectal, kidney, bladder, and melanoma cancers. Downregulation of these hypoxia-inducible targets associated with poor prognosis, suggesting that hypoxia-induced apoptosis contributes to
p53
-mediated tumor suppression and treatment response. Induction of
p53
targets, PHLDA3, and a specific INPP5D transcript mediated apoptosis in response to hypoxia through AKT inhibition. Moreover, pharmacological inhibition of AKT led to apoptosis in the hypoxic regions of
p53
-deficient tumors and consequently increased radiosensitivity. Together, these results identify mediators of hypoxia-induced
p53
-dependent apoptosis and suggest AKT inhibition may improve radiotherapy response in
p53
-deficient tumors.
...
PMID:Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT. 2596 49